91 related articles for article (PubMed ID: 16246554)
1. Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp.
Tsukamoto S; Yoshida T; Hosono H; Ohta T; Yokosawa H
Bioorg Med Chem Lett; 2006 Jan; 16(1):69-71. PubMed ID: 16246554
[TBL] [Abstract][Full Text] [Related]
2. Stereochemical studies of hexylitaconic acid, an inhibitor of p53-HDM2 interaction.
Nakahashi A; Miura N; Monde K; Tsukamoto S
Bioorg Med Chem Lett; 2009 Jun; 19(11):3027-30. PubMed ID: 19414261
[TBL] [Abstract][Full Text] [Related]
3. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions.
Hara T; Durell SR; Myers MC; Appella DH
J Am Chem Soc; 2006 Feb; 128(6):1995-2004. PubMed ID: 16464101
[TBL] [Abstract][Full Text] [Related]
4. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Parks DJ; LaFrance LV; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Schubert C; Koblish HK; Zhao S; Franks CF; Lattanze J; Carver TE; Cummings MD; Maguire D; Grasberger BL; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3310-4. PubMed ID: 16600594
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of the hdm2-p53 interaction.
Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
[TBL] [Abstract][Full Text] [Related]
6. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
[TBL] [Abstract][Full Text] [Related]
7. Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.
Cummings MD; Schubert C; Parks DJ; Calvo RR; LaFrance LV; Lattanze J; Milkiewicz KL; Lu T
Chem Biol Drug Des; 2006 Mar; 67(3):201-5. PubMed ID: 16611213
[TBL] [Abstract][Full Text] [Related]
8. Miniature protein inhibitors of the p53-hDM2 interaction.
Kritzer JA; Zutshi R; Cheah M; Ran FA; Webman R; Wongjirad TM; Schepartz A
Chembiochem; 2006 Jan; 7(1):29-31. PubMed ID: 16397877
[No Abstract] [Full Text] [Related]
9. Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists.
Marugan JJ; Leonard K; Raboisson P; Gushue JM; Calvo R; Koblish HK; Lattanze J; Zhao S; Cummings MD; Player MR; Schubert C; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3115-20. PubMed ID: 16630722
[TBL] [Abstract][Full Text] [Related]
10. Beta-peptides with improved affinity for hDM2 and hDMX.
Harker EA; Daniels DS; Guarracino DA; Schepartz A
Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction.
Fasan R; Dias RL; Moehle K; Zerbe O; Obrecht D; Mittl PR; Grütter MG; Robinson JA
Chembiochem; 2006 Mar; 7(3):515-26. PubMed ID: 16511824
[TBL] [Abstract][Full Text] [Related]
12. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction.
Plante JP; Burnley T; Malkova B; Webb ME; Warriner SL; Edwards TA; Wilson AJ
Chem Commun (Camb); 2009 Sep; (34):5091-3. PubMed ID: 20448956
[TBL] [Abstract][Full Text] [Related]
13. Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Pan W; Lahue BR; Ma Y; Nair LG; Shipps GW; Wang Y; Doll R; Bogen SL
Bioorg Med Chem Lett; 2014 Apr; 24(8):1983-6. PubMed ID: 24656661
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel mdm2 binding peptides by phage display.
Böttger V; Böttger A; Howard SF; Picksley SM; Chène P; Garcia-Echeverria C; Hochkeppel HK; Lane DP
Oncogene; 1996 Nov; 13(10):2141-7. PubMed ID: 8950981
[TBL] [Abstract][Full Text] [Related]
15. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.
Parks DJ; Lafrance LV; Calvo RR; Milkiewicz KL; Gupta V; Lattanze J; Ramachandren K; Carver TE; Petrella EC; Cummings MD; Maguire D; Grasberger BL; Lu T
Bioorg Med Chem Lett; 2005 Feb; 15(3):765-70. PubMed ID: 15664854
[TBL] [Abstract][Full Text] [Related]
16. Small molecules targeting p53 to improve antitumor therapy.
Beretta GL; Gatti L; Benedetti V; Perego P; Zunino F
Mini Rev Med Chem; 2008 Aug; 8(9):856-68. PubMed ID: 18691143
[TBL] [Abstract][Full Text] [Related]
17. Siladenoserinols A-L: new sulfonated serinol derivatives from a tunicate as inhibitors of p53-Hdm2 interaction.
Nakamura Y; Kato H; Nishikawa T; Iwasaki N; Suwa Y; Rotinsulu H; Losung F; Maarisit W; Mangindaan RE; Morioka H; Yokosawa H; Tsukamoto S
Org Lett; 2013 Jan; 15(2):322-5. PubMed ID: 23268733
[TBL] [Abstract][Full Text] [Related]
18. Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence.
Kane SA; Fleener CA; Zhang YS; Davis LJ; Musselman AL; Huang PS
Anal Biochem; 2000 Feb; 278(1):29-38. PubMed ID: 10640350
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
[TBL] [Abstract][Full Text] [Related]
20. Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction.
Malloy KL; Choi H; Fiorilla C; Valeriote FA; Matainaho T; Gerwick WH
Bioorg Med Chem Lett; 2012 Jan; 22(1):683-8. PubMed ID: 22104152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
